MTSS1 curtails lung adenocarcinoma immune evasion by promoting AIP4-mediated PD-L1 monoubiquitination and lysosomal degradation

Immune checkpoint blockade (ICB) therapy targeting PD-1/PD-L1 has shown durable clinical benefits in lung cancer. However, many patients respond poorly to ICB treatment, underscoring an incomplete understanding of PD-L1 regulation and therapy resistance. Here, we find that MTSS1 is downregulated in...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Yuan, Jia, Zhenchang, Liang, Chenxi, He, Yunfei, Cong, Min, Wu, Qiuyao, Tian, Pu, He, Dasa, Miao, Xiang, Sun, Beibei, Yin, Yue, Peng, Chao, Yao, Feng, Fu, Da, Liang, Yajun, Zhang, Peiyuan, Xiong, Hua, Hu, Guohong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Nature Singapore 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9944270/
https://www.ncbi.nlm.nih.gov/pubmed/36810288
http://dx.doi.org/10.1038/s41421-022-00507-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9944270/
https://www.ncbi.nlm.nih.gov/pubmed/36810288
http://dx.doi.org/10.1038/s41421-022-00507-x

Ejemplares similares